GeNeuro Reports 2020 Half-Year Results And Provides Corporate Update
(WorldNews Switzerland)

GeNeuro Reports 2020 Half-Year Results And Provides Corporate Update 29 Sep 2020 18:30 CEST Company Name GENEURO ISN CH0308403085 Market Euronext Symbol GNRO Successful €17.5 million private placement Cash position of €10.5 million as of June 30, 2020 All activities funded until mid-2022 Launch of temelimab new Phase 2 trial in multiple sclerosis (MS) at the Academic Specialist Center (ASC) of the Karolinska Institutet in Stockholm Reinforcement of the management team with the appointments of Pr. David Leppert as Chief Medical Officer and Dr. Jean-François Arrighi Chief Development Officer Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical...